Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRIT: Inclisiran Implementation in Primary Care
NCT04807400Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2021
- Primary completion
- Jan 2023
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 3 trial of inclisiran in hypercholesterolemia, sponsored by Novartis. Started Jul 2021; status: completed.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT04807400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04807400.